Background and Purpose-The purpose of this study was to investigate time delays, adherence to guidelines, and their impact on outcomes in patients with warfarin-associated intracerebral hemorrhage transferred from community emergency departments to a comprehensive stroke center. Methods-We collected demographic, clinical, transfer time, treatment, and outcome data for patients transferred to our institution with warfarin-associated intracerebral hemorrhage from community emergency departments. Results-Among 928 patients with intracerebral hemorrhage, 56 (6%) with warfarin-associated intracerebral hemorrhage (median international normalized ratio, 2.55) were transferred to the comprehensive stroke center. Twenty patients received no acute reversal therapy before transfer, only 4 of whom had international normalized ratios Յ1.4 in the community emergency department. Median time of emergency department stay was 3.66 hours and median time to initiation of acute reversal therapy was 4.48 hours. Those who received Ն3 U of fresh-frozen plasma or recombinant activated Factor VIIa (11 patients) before transfer had lower repeat international normalized ratios and better discharge dispositions than those treated less aggressively. Conclusions-Treatment of warfarin-associated intracerebral hemorrhage in community emergency departments is often suboptimal and does not adhere to published guidelines. Treating coagulopathy aggressively before interhospital transfer may improve outcomes and warrants further investigation. (Stroke. 2012;43:00-00.)
W arfarin-associated intracerebral hemorrhage (WAICH) is a high mortality disease of increasing prevalence. 1, 2 American Heart Association/American Stroke Association guidelines emphasize rapid reversal of elevated international normalized ratio (INR) in WAICH but do not suggest a time goal. 3 Some recommend INR normalization within 2 hours given that delayed reversal may contribute to both early and prolonged hematoma expansion. 4 -8 Because patients with WAICH often present to community emergency departments (EDs), reversal within 2 hours may require therapy before arrival at a comprehensive stroke center (CSC). Limited data exist on the timeline of events, therapies administered, and optimal ED management of WAICH before transfer to CSCs. We sought to describe the ED treatment timeline and variability in reversal therapy in patients with WAICH transferred to our CSC.
Materials and Methods
With Institutional Board Review and using a prospective registry of intracerebral hemorrhage admissions, we selected consecutive patients with WAICH transferred from 24 regional community EDs and collected demographic, clinical, laboratory, radiographic, and discharge disposition data. We excluded patients transferred from inpatient services, traumatic intracerebral hemorrhage, and those on multiple anticoagulants or with underlying secondary causes for hemorrhage. Key time points, ED laboratory values, and therapies administered within the first 24 hours of presentation were abstracted by retrospective chart review. We defined acute reversal therapy as fresh-frozen plasma (FFP) or recombinant activated Factor VIIa; no patient received prothrombin complex concentrate.
We compared 2 acute reversal therapy groups: Group 1: 3 or more units of FFP or any recombinant activated Factor VIIa before transfer (early reversal); and Group 2: 2 or fewer units of FFP and no recombinant activated Factor VIIa before transfer (nonearly reversal). Three units of FFP was selected as the cutoff between groups because this approximates the minimal volume of FFP required to normalize INR in warfarin users. 9 Mean values and SDs or median values and interquartile ranges were determined and we compared demographic, clinical, hematoma, and discharge characteristics between the 2 groups using Fisher exact tests, Student t tests, and Mann-Whitney U tests as appropriate. Probability values Ͻ0.05 were significant and analyses were performed using SPSS 16.0 (Chicago, IL).
Results
Between August 2006 and May 2011, 928 patients were treated at our CSC for intracerebral hemorrhage. Fifty-six (6%) patients were interhospital transfers with WAICH meeting study criteria. Table 1 summarizes therapies administered. Twenty patients received no acute reversal therapy before transfer, only 4 of whom had initial INR Յ1.4 in the community ED. Only 5 of the remaining 16 patients had documented reasons for nonreversal: physician preference to expedite transfer, inability to cross match, transport was ready to depart, and 2 instances of delay to thaw FFP. Only 33 patients received vitamin K before transfer. Fourteen patients underwent neurosurgical intervention with no difference between groups (data not shown).
Demographic, clinical, hematoma, and timeline data are shown in Table 2 . There were no differences in age, initial INR, Glasgow Coma Scale score, or hemorrhage characteristics between treatment groups. The early reversal group had lower mean INR at the CSC (1.53 versus 2.05; Pϭ0.02).
The median time in the ED was 3.66 hours, but the early reversal group remained in the ED longer (median, 5.35 versus 3.65 hours; Pϭ0.004). The median time from presentation to initiation of acute reversal therapy was 4.48 hours and, among those who received any reversal before transfer, did not differ between groups. Only 5 patients received acute reversal therapy within 2 hours of presentation.
In-hospital mortality was 37% (30% in early reversal versus 39% in nonearly reversal, Pϭ0.72). Among those with initial INR Ͼ1.4, early reversal was associated with a good discharge outcome, which was defined as discharge home, to the same premorbid level of care, or to acute rehabilitation (70% versus 29%; Pϭ0.03).
Discussion
In patients with WAICH transferred from community EDs to a CSC, initiation of acute anticoagulation reversal therapy was delayed nearly 5 hours. Only 5 patients in our study initiated acute reversal therapy within 2 hours of presentation despite risks of both early and prolonged hematoma expansion without rapid, complete reversal. 5, 6, 8 Before transfer, only one in 5 patients received sufficient acute reversal. 9 Patients who received more aggressive reversal therapy had better outcomes despite longer transfer delays. These observations suggest that optimal reversal therapy should be initiated before transfer even at the cost of transfer delay.
Our findings suggest adherence to guidelines in the treatment of WAICH in community EDs is poor. We speculate that ED physicians may expedite transfer to CSCs because of concerns over lack of neurosurgical support. However, expediting transfer is at the cost of inadequate anticoagulation reversal. Lack of availability of, or familiarity with, acute reversal agents and time to thaw FFP may also influence transfer decisions.
Small sample size, insufficient detail in ED records, and the retrospective design prevented us from exploring the effect of aggressive acute reversal therapy on hematoma size and expansion and clinical deterioration before transfer. Although our study has limitations and requires replication in larger prospective cohorts, we conclude that acute reversal therapy is often inadequately provided to patients with WAICH in community EDs. Aggressive reversal therapy before transfer, even at the cost of transfer delay, may be associated with lower INR values posttransfer and better clinical outcomes. A concerted effort to educate community hospitals and emphasize uniform, guidelinedriven approaches to anticoagulation reversal before transfer to CSCs is needed.
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Table 1. Key Interventions at Community Emergency Departments and the CSC Within the First 24 H From Presentation
Treatments Within 24 h of presentation No.
Pretransfer vitamin K 33
Pretransfer 
